000695986 000__ 06985cam\a2200445Ii\4500
000695986 001__ 695986
000695986 005__ 20230306135510.0
000695986 006__ m\\\\\o\\d\\\\\\\\
000695986 007__ cr\cnu---unuuu
000695986 008__ 131112s2014\\\\nyua\\\\o\\\\\000\0\eng\d
000695986 020__ $$a9781461482024 $$qelectronic book
000695986 020__ $$a146148202X $$qelectronic book
000695986 020__ $$z9781461482017
000695986 020__ $$z1461482011
000695986 035__ $$aSP(OCoLC)ocn862814496
000695986 035__ $$aSP(OCoLC)862814496
000695986 040__ $$aN$T$$beng$$erda$$epn$$cN$T$$dGW5XE$$dYDXCP$$dCOO$$dOHS$$dVAM
000695986 043__ $$an-us---
000695986 049__ $$aISEA
000695986 050_4 $$aK3601
000695986 08204 $$a344.0419$$222
000695986 1001_ $$aBrougher, Joanna T.,$$eauthor.
000695986 24510 $$aIntellectual property and health technolgies$$h[electronic resource] :$$bbalancing innovation and the Public Health /$$cJoanna T. Brougher.
000695986 264_1 $$aNew York :$$bSpringer,$$c2014.
000695986 300__ $$a1 online resource (260 pages) :$$billustrations.
000695986 336__ $$atext$$btxt$$2rdacontent
000695986 337__ $$acomputer$$bc$$2rdamedia
000695986 338__ $$aonline resource$$bcr$$2rdacarrier
000695986 5050_ $$a1. Introduction to Intellectual Property -- Introduction -- The Meaning of "Intellectual Property" -- Types of Intellectual Property Protection -- Copyright -- Trademarks -- Trade Secrets -- Patents -- Requirements -- Underlying Theory of Intellectual Property -- Basis of Intellectual Property Law -- The U.S. Patent System -- United States Patent and Trademark Office -- Supreme Court -- Congress -- Summary -- References -- 2. Obtaining, Enforcing and Defending Patents -- Obtaining Patent Protection -- Patentable Subject Matter -- Utility -- Novelty -- Nonobviousness -- Written Description and Enablement -- Enforcement of Patents -- Types of Patent Infringement -- Determination of Infringement -- Remedies for Infringement -- Defenses -- Invalidity -- Inequitable Conduct -- Exhaustion -- Exhaustion and Self-Replicating Technologies -- Experimental Use -- Five Important Facts to Remember About Patents -- Summary -- References -- 3. Gene Patents -- History of Gene Patenting -- Chakrabarty and the Rise of Gene Patents -- Chakrabarty's Legacy -- The Harvard Oncomouse and the Patenting of Higher Level Life Forms -- The Current Controversy -- Public Health Implications -- Access to Medical Treatment -- Quality of Medical Treatment -- Innovation -- Summary -- References -- 4. Medical Procedure Patents -- History of Medical Procedure Patents -- The Patent Law Compromise -- Who is Protected -- The Loophole for Medical Devices -- The Unenforceable Patent Right -- Medical Procedure Patents as "Process" Under Section 101 -- A Possible Shift in the Trend: In re Bilski and the "Machine or Transformation" Test -- Aftermath of Bilski -- Immunizations: Classen Immunotherapies, Inc. v. Biogen -- In Vitro Diagnostics: Prometheus Laboratories, Inc. v. Mayo Collaborative Services -- Diagnostic Testing: Myriad Genetics v. Association for Molecular Pathology (AMP) -- Public Health Implications -- Ethical Issues --
000695986 5050_ $$aAcademic Access -- Patient Privacy -- Access to Medical Treatment -- Impact on Innovation -- Infringement Liability -- Summary -- References -- 5. Rights and Roles of Universities and Inventors -- Researcher and Inventor -- Publish or Perish -- Determining Inventorship -- The Bayh-Dole Act: Stimulating Commercialization of University Research -- IP Policies and Assignment Provisions -- Stanford v. Roche -- Government's March-in Rights -- Effects of the Bayh-Dole Act -- Technology Transfer: Transferring University Technology to the Private Sector -- Summary -- References -- 6. Drug Development: Managing the Patent and FDA Processes -- Overview of Drug Development -- Reconciling Patent Protection with the Drug Development Process -- Extending the Life and Value of a Product -- Patent Exclusivities -- Patent Term Adjustments for Delays Due to USPTO Approval -- Patent Term Extensions for Delays Due to Regulatory Approval -- Nonpatent Exclusivities -- New Chemical Entity Exclusivity -- New Clinical Study Exclusivity -- Generic Drug Exclusivity -- Generic Biologic Exclusivity -- Orphan Drug Exclusivity -- Pediatric Exclusivity -- Implications for the Public's Health -- Misuse of Exclusivities -- Disproportional Incentives -- Minimal Health Benefits -- Summary -- References -- 7. Patent Battles Part I: The Hatch Waxman Act and Small-Molecule Drugs -- Generic Drugs -- Effect of Generic Drugs on the Market -- The Hatch-Waxman Act -- Restoring Patent Term and Providing Additional Market Exclusivity -- Safe Harbor -- Abbreviated New Drug Application (ANDA) -- Consequences of the Hatch-Waxman Act -- Evergreening -- Patenting of Obvious Inventions -- Authorized Generics -- Pay-for-Delay Settlement Agreements -- Multiple Orange Book Listings -- Continuation Application Practice -- Public Health Implications -- Availability of Generics Drugs -- Innovation of New Drugs -- Summary -- References --
000695986 5050_ $$a8. Patent Battles Part II: The Biosimilars Act and Biologics -- Overview of Biologics -- Regulation of Biologies in the United States -- Biologics Price Competition and Innovation Act (The "Biosimilars Act") -- Biosimilar Versus Interchangeable -- Brand-Name Exclusivities -- Generic Exclusivities -- Patent Dispute Resolution -- Public Health Implications -- Access to Biosimilars -- Achieving "Biosimilarity" or "Interchangeability" Status -- Uncertain Exclusivity Timelines -- Loop Holes for Brand-Name Biologics -- Promoting Innovation -- Summary -- References -- 9. International Patent Law, Trade Law, and Access to Drugs -- International Institutions Governing International Patent Law -- World Intellectual Property Organization -- World Trade Organization -- Agreement on Trade Related Aspects of Intellectual Property Rights (TRIPS Agreement) -- Exception to TRIPS: Compulsory Licensing -- Doha Declaration -- Amendment to TRIPS -- Compulsory Licensing Case Studies -- India's Patent Laws -- Evergreening Patents and the Battle over Glivec -- Compliance with TRIPS -- Constitutional Validity of Section 3(d) -- Patentability of Glivec -- Compulsory Licensing in India -- Why India is Important -- Drug Pricing and Access to Medicines -- Competition from Generics -- Price Differentiation -- Parallel Imports -- Corporate Donations -- Patents and Access to Drugs -- Stimulating New Drug Innovation -- Prize System: Health Impact Fund -- Patent Pools -- Open Source Model for Drug Discovery and Development -- Summary -- References.
000695986 506__ $$aAccess limited to authorized users.
000695986 588__ $$aDescription based on print version record.
000695986 650_0 $$aMedicine$$xPatents$$xLaw and legislation.
000695986 650_0 $$aHealth services accessibility$$xLaw and legislation.
000695986 77608 $$iPrint version:$$aBrougher, J.$$tIntellectual property and health technolgies$$z9781461482017$$w(OCoLC)862716415
000695986 85280 $$bebk$$hSpringerLink
000695986 85640 $$3SpringerLink$$uhttps://univsouthin.idm.oclc.org/login?url=http://dx.doi.org/10.1007/978-1-4614-8202-4$$zOnline Access
000695986 909CO $$ooai:library.usi.edu:695986$$pGLOBAL_SET
000695986 980__ $$aEBOOK
000695986 980__ $$aBIB
000695986 982__ $$aEbook
000695986 983__ $$aOnline
000695986 994__ $$a92$$bISE